Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for MYRBETRIQ
- A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)
- Using Mirabegron to Increase BP in Patients With POTS
- MIrabegron and Physiological Function in Cold Environments
- Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
- ADRB3 Signaling Pathway in Human Adipose Tissue
- A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity
- Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women
- Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
- Activation of Brown Adipose Tissue Metabolism Using Mirabegron
- Mechanisms for Activation of Beige Adipose Tissue in Humans
- A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
- Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)
- Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
- Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron
- Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study
- Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury
- Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder
- Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta 3-Adrenergic Receptor Agonists
- Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
- Brown Fat Activation Study
- Mirabegron For Erectile Dysfunction
- A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
- Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain
- Mirabegron in Parkinson Disease and Impaired Cognition
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
- Mirabegron and Urinary Urgency Incontinence
- Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
- Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
- Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
- Treatment of Incontinence Without Memory Problems
- Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
- A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
- Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults
- Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
- Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
- Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
- A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
- Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
- Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
- A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
- Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
- This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
- A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
- A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
- A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
Clinical trials list
click for details